BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Regulation FD Disclosure

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01. Regulation FD Disclosure.

On January 8, 2017, BioCryst Pharmaceuticals, Inc. (BioCryst)
announced that Health Canada has approved RAPIVAB (peramivir
injection), an intravenous (I.V.) treatment for acute,
uncomplicated influenza. The approval triggered a $2.0 million
milestone payment to BioCryst to the License Agreement, dated as
of June 16, 2015, by and between BioCryst and Seqiris UK Limited.

On January 8, 2017, the Company issued a news release announcing
the events described in this Item 7.01. A copy of the news
release is filed as Exhibit 99.1 hereto and is incorporated
herein by reference.

The information furnished in this Item 7.01 is not deemed filed
for purposes of Section 18 of the Securities Exchange Act of
1934, as amended, is not subject to the liabilities of that
section and is not deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking
statements, including statements regarding future results,
performance or achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause
BioCrysts actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking
statements. These statements reflect our current views with
respect to future events and are based on assumptions and subject
to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements.
Some of the factors that could affect the forward-looking
statements contained herein include: that Health Canada may not
provide regulatory approval for any use of RAPIVAB for certain
patient populations or that the approval may be limited. Please
refer to the documents BioCryst files periodically with the
Securities and Exchange Commission, specifically BioCrysts most
recent Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and Current Reports on Form 8-K, all of which identify
important factors that could cause the actual results to differ
materially from those contained in BioCrysts projections and
forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


Press Release dated January 8, 2017 entitled BioCryst
Receives Health Canada Approval for RAPIVAB for the
Treatment of Influenza

About BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Recent Trading Information

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) closed its last trading session up +0.20 at 7.13 with 1,034,888 shares trading hands.

An ad to help with our costs